We are thrilled to announce that our partner, STADA Group, has received European Commission decision for full approval of our treatment of #IgANephropathy. The granting of the full approval results in a significantly broader label for patients with primary #IgAN. Learn more: https://lnkd.in/gEhnC23j
Calliditas Therapeutics
Tillverkning av läkemedel
Stockholm, Stockholm County 10 958 följare
Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the lives of patients.
Om oss
Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
- Webbplats
-
https://www.calliditas.se/
Extern länk för Calliditas Therapeutics
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 51–200 anställda
- Huvudkontor
- Stockholm, Stockholm County
- Typ
- Publikt aktiebolag
- Grundat
- 2004
Adresser
Anställda på Calliditas Therapeutics
-
Anna Axelman
Pharmaceutical Project Associate Director at Calliditas Therapeutics AB
-
David Ferraro
Pharmaceutical/Biotech Executive, VP of Sales at Calliditas Therapeutics, Commercial Strategy & Development, Start-up, Sales Leadership, Marketing…
-
Wendy Rockwell
Pioneering Vision * Powering Change | Market Access | Contract Lead | National Payers | Federal Markets | Regional Payers | Medicare | Medicaid |…
-
Ingela Keding Messler
Uppdateringar
-
It has been a busy year at Calliditas as we’ve spent time with nephrologists, patients, and the #RareDisease community. Spanning key conferences to advocacy work, we are excited for more to come throughout the rest of 2024!
-
Of our novel NOX inhibitor platform, setanaxib is the first to reach the clinical trial stage. In the next 12 months, we expect additional milestones to come, including multiple clinical trial data readouts and additional indications. Learn more: https://lnkd.in/g3AKkAvj
-
Our CEO, Renee Aguiar-Lucander, will be attending the WOMEN IN NEPHROLOGY Leadership Conference from August 9th to 10th at UCLA. Celebrating the 40th anniversary of Women In Nephrology, WIN has endeavored to meet its mission to promote professional development for women and men in nephrology and to advocate for education and research, relevant to women's health. We are honored to have Renée represent us here. Learn more: https://lnkd.in/gGrJF_ub
-
-
IgA nephropathy is estimated to affect 130,000 to 150,000 patients in the U.S., showing an urgent need for treatment. Our treatment is the first and only fully approved treatment for IgAN and is approved based on a measure of kidney function. Learn more: https://lnkd.in/gpeMqnbw
-
Our CEO, Renee Aguiar-Lucander, understands the value of our treatment option and what it provides for the #IgANephropathy patient community. That is why no time was wasted in the journey towards FDA approval. Listen more: https://lnkd.in/gSaXaUgr
-
At #ERA2024, we connected with industry leaders and physicians on IgA nephropathy (IgAN). Our educational tool, IgANexus, is developed in collaboration with experts who are focused on advancing scientific education in #IgAN. See more: https://lnkd.in/ejnKnpAa
-
Dealing with a disease like IgA nephropathy (#IgAN) can be a lot, as it can impact patients physically and emotionally. Finding credible resources is critical to supporting patients with IgAN. Explore IgAN Connect now: https://lnkd.in/eYp9aRTH
-
Our CEO will be speaking at the upcoming #Biotech CEO Summit sponsored by Demy-Colton. We look forward to her thoughts around achieving approval across geographies and the journey to creating a successful, sustainable #RareDisease company. Learn more: https://lnkd.in/guPXxpzh
-
Our partnerships with organizations like the National Kidney Foundation and The IgA Nephropathy Foundation help us connect to the patient community. We are proud to sponsor a joint initiative between these partners called “Improving Quality Care for Patients Living with IgAN.” This will help us identify barriers and solutions to optimal communications during office visits. We’re excited to be part of this initiative.